IPOs - All articles

  • ChiNext reform a step forward but valuation, quality concerns rise

    China said this week that it will radically overhaul the ChiNext board, approving a registration-based system for equity fundraising on the Shenzhen Stock Exchange’s start-up focused bourse. This is an important step by the regulator to shift to more market-driven capital markets ─ but plenty of concerns remain. Addison Gong reports.

    • 29 Apr 2020
  • HKEX rejigs listing division leadership

    The Hong Kong Stock Exchange has shaken up its listing division, promoting Stephanie Lau and Katherine Ng to leadership positions.

    • 29 Apr 2020
  • China brings registration-based IPO system to ChiNext

    The China Securities Regulatory Commission (CSRC) has kicked off big reforms to the ChiNext board, in a bid to revive its appeal once again to fast growing and high tech companies that have been favouring the Shanghai’s Star market since its launch last year.

    • 28 Apr 2020
  • Central China New Life pre-markets Hong Kong IPO

    Property management company Central China New Life carried out accelerated pre-marketing for its Hong Kong IPO this week, said a source close to the deal.

    • 27 Apr 2020
  • Ebang eyes $100m from US listing

    China's Ebang International Holdings, a cryptocurrency mining hardware maker, is planning a US IPO that could raise up to $100m. It follows in the footsteps of Canaan Creative, which listed last November but has since seen its stock price tumble about 53%.

    • 27 Apr 2020
  • Indian regulator loosens its grip to give fillip to ECM deal flow

    India’s equity capital markets have welcomed a temporary loosening of rules around IPOs and rights issues, with bankers saying it could help push out deals as soon as market conditions stabilise. Jonathan Breen reports.

    • 23 Apr 2020
  • Akesobio prices Hong Kong IPO at top end

    Akesobio has bagged HK$2.58bn ($332.9m) from its IPO after sealing the trade at the top of the marketed price range, according to a banker on the deal.

    • 20 Apr 2020
  • Xiaomi-backed Kingsoft Cloud tests appetite for US IPO

    Kingsoft Cloud Holdings has launched a virtual pre-deal investor education process for its $100m Nasdaq IPO, according to a source close to the deal.

    • 20 Apr 2020
  • Retail, institutional investors storm Akesobio IPO

    Bankers working on Akesobio’s IPO are preparing for a tough allocation process as a flood of retail demand for the Hong Kong listing is set to leave little for institutional accounts, said a source close to the deal.

    • 16 Apr 2020
  • China’s coronavirus response: capital markets take centre stage

    China’s government has won plaudits for its response to the Covid-19 coronavirus. That praise should extend to its capital markets.

    • 14 Apr 2020
  • CSRC raises red flags with Star duo

    The China Securities Regulatory Commission (CSRC) has penalised two Star market companies for failing to make sufficient risk disclosures in their IPO documents. The duo were among the first batch of 25 companies to list on the Star board.

    • 14 Apr 2020
  • Akesobio kicks off virtual roadshow for HK IPO

    Akesobio, a Chinese biopharmaceutical firm, has launched an online-only roadshow for its up to HK$2.58bn ($332.9m) IPO amid numerous country-wide lockdowns globally to combat the Covid-19 coronavirus pandemic.

    • 14 Apr 2020
  • AMTD debuts dual-class shares on SGX, stock surges

    US-listed AMTD International floated on the Singapore Exchange this week, debuting dual-class shares on the southeast Asian bourse through a secondary offering.

    • 09 Apr 2020
  • WeDoctor adds new bank for Hong Kong IPO

    WeDoctor, a Chinese healthcare app, has added Citi to the syndicate team of its Hong Kong IPO, GlobalCapital Asia understands.

    • 09 Apr 2020
  • CSRC mulls faster IPO approvals for Covid-19 affected firms

    The China Securities Regulatory Commission (CSRC) is speeding up the approval process for IPOs and follow-ons for companies impacted by the Covid-19 pandemic, GlobalCapital China understands.

    • 09 Apr 2020
  • Akesobio set to launch $300m Hong Kong IPO

    Chinese biopharmaceuticals firm Akesobio is preparing to launch bookbuilding for its IPO next week, according to a source close to the deal.

    • 08 Apr 2020
  • Akesobio readies Hong Kong listing

    Chinese biopharmaceutical firm Akesobio has got the greenlight from the Hong Kong Stock Exchange for its IPO, which is expected to raise $200m to $300m, according to a source familiar with the matter.

    • 06 Apr 2020
  • Fudan-Zhangjiang Bio-Pharma all set for Star board dual-listing

    Hong Kong-listed Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co has won approval from Shanghai’s bourse to list shares on the Star board.

    • 06 Apr 2020
  • Thai state energy giant pushes on with PTTOR listing

    Thailand’s state-owned oil and gas conglomerate PTT is moving forward with the IPO of its subsidiary PTT Oil and Retail Business.

    • 03 Apr 2020